Residual inflammatory risk appeared related to weight, atherogenic lipid profile and biomarkers of inflammation, but not to glycaemic control in type 1 diabetes

Background

Mortality associated with atherosclerotic cardiovascular disease reduces average life expectancy by more than a decade in type 1 diabetes. Systemic inflammation drives atherosclerosis, and the concept of residual inflammatory risk (defined by high-sensitivity C-reactive protein (hsCRP) ≥2 mg/l) poses a potential, new therapeutic target for lowering residual cardiovascular risk in type 1 diabetes. However, the characteristics of individuals with residual inflammatory risk in type 1 diabetes are unknown.

Purpose

Identify differences in relevant demographics, clinical and paraclinical parameters for individuals with residual inflammatory risk as compared to those without in type 1 diabetes.

Methods

Baseline characteristics as stratified for CRP ≥2 mg/l were analysed in 105 patients with type 1 diabetes participating in a previously published clinical trial. The study population was sampled to represent the broad background population struggling with glycaemic control and with a high cardiovascular risk.

Results

Residual inflammatory risk was seen in 39.1% of the study population. Compared to individuals without residual inflammatory risk, individuals with residual inflammatory risk were more frequently women, had increased body weight, body mass index and dual-energy X-ray absorptiometry (DXA)-assessed fat mass and exhibited elevated levels of low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) and total cholesterol as well as triglycerides, interleukin 6 and tumour necrosis factor alpha (Table 1). Glycated haemoglobin, blood pressure and markers of renal function were similar between groups (Table 1).

Conclusion

In the present cohort of individuals with type 1 diabetes, residual inflammatory risk was seen in 39.1% (similar to what is observed outside of type 1 diabetes) and appeared related to overweight/obesity, an atherogenic lipid profile and circulating biomarkers of inflammation but not to glycaemic control, blood pressure or renal function.

Funding Acknowledgement

Type of funding sources: Private company. Main funding source(s): AstraZenecaHerlev Gentofte Hospital

Prognostic utility of early systolic lengthening by speckle tracking echocardiography in patients with type 2 diabetes

Background

Early systolic lengthening (ESL) has recently recognized as a predictor of cardiovascular events in patients with myocardial ischemia. Our aim was to evaluate the prognostic value of ESL in patients with type 2 diabetes.

Methods

In this prospective study we conducted speckle tracking examinations in 743 patients with type 2 diabetes (62% male; age 63±10 years; diabetes duration 11 [5, 17] years). Patients were free from interventricular conduction disturbances, atrial fibrillation, heart failure and ischemic heart disease at study inclusion. We assessed the ESL index, defined as: (−100 x [peak positive systolic strain / global longitudinal strain (GLS)]), and duration of ESL, defined as time from onset of QRS complex on the electrocardiogram to time of peak positive systolic strain. Measurements were averaged from 18 myocardial segments.

Results

During the median follow-up time of 4.8 years [IQR 4, 5.3 years], 93 (13%) patients experienced major adverse cardiovascular events (MACE), a composite of incident heart failure, myocardial infarction and cardiovascular death. Because GLS modified the association with MACE (P interaction <0.05), the population was stratified by the median GLS value (low >−15% and high ≤−15%). In patients with low GLS, the ESL index (HR 1.47 per 1% increase [1.12 to 1.93], P=0.005) and ESL duration (HR 1.73 per 1ms increase [1.10 to 2.72], P=0.017) were associated with MACE. Both associations remained significant in multivariable models adjusted for clinical, echocardiographic and speckle tracking measurements (Figure). No associations were found in patients with high GLS (Figure).

Conclusion

Assessment of ESL yields novel and independent prognostic information on major adverse cardiovascular events in patients with diabetes type 2 and reduced longitudinal strain.

Forest plot: ESL and risk of MACE by GLS

Funding Acknowledgement

Type of funding source: None

3080Postsystolic shortening yields novel and independent prognostic information on cardiovascular events and mortality in patients with type 2 diabetes

Background

Cardiovascular disease is the leading cause of death and disability in patients with type 2 diabetes. We aimed to evaluate if postsystolic shortening, a marker of impaired myocardial function, may provide prognostic information on cardiovascular events and mortality in patients with type 2 diabetes.

Method

We prospectively studied 783 patients with diabetes type 2 (63% male, age 65 [58, 70] years; HbA1c 54 [48, 65] mmol/mol; diabetes duration 11 [6, 17] years) who underwent speckle tracking echocardiography. Patients with left bundle branch block, atrial fibrillation and a history of heart failure and myocardial infarction were excluded. The primary endpoint was the composite of incident heart failure, myocardial infarction and cardiovascular death. The secondary endpoint was all-cause death. We defined the postsystolic index (PSI) as: [100x (maximum strain in cardiac cycle – peak systolic strain)/ (maximum strain in cardiac cycle)].

Results

During the median follow-up of 4.9 years [4.2, 5.3], 87 patients (11%) reached the primary endpoint and 80 (10%) died from any cause. Each 1% increase in the PSI was associated with the primary (HR 1.07 95% CI 1.02–1.13, P<0.001, Fig A) and secondary endpoint (HR 1.09 95% CI 1.04–1.14, P<0.001, Fig B). After adjusting for age, sex, hypertension, smoking, duration of diabetes, cholesterol, eGFR, left ventricular ejection fraction and mass index, E/A-ratio, deceleration time and left atrial volume index, the PSI remained an independent predictor of both endpoints; primary (HR 1.07 per 1% increase 95% CI 1.01–1.14, P=0.028) and secondary endpoint (HR 1.07 per 1% increase, 95% CI 1.01–1.14, P=0.022).

PSI and the endpoints

Conclusion

In patients with type 2 diabetes, assessment of PSI yields novel and independent prognostic information on cardiovascular events and mortality. Hence, PSI may offer guidance on risk stratification in patients with type 2 diabetes.

P3427Prognostic performance of echocardiography, electrocardiogram, albuminuria, plasma proBNP and hs-TnI in patients with type 2 diabetes

Background

A range of diagnostic tests including echocardiography, albuminuria, electrocardiogram (ECG), plasma measurement of high sensitivity troponin T (hs-TnI) and pro-brain natriuretic peptide (proBNP) have been suggested as cardiovascular (CV) risk predictors in patients with type 2 diabetes. In this study we examined prognostic yield from these risk markers.

Methods

A total of 1,030 out-patients followed at a large secondary care diabetes clinic were recruited. Echocardiography was considered feasible in patients in sinus rhythm with adequate image quality (n=886). Abnormal echocardiography was defined as a left ventricular ejection fraction (LVEF) <50%; a ratio of early diastolic mitral inflow velocity to early diastolic septal annular velocity (E/e'septal) ≥15; increased left ventricular mass index (>95 g/m2 for women and >115 g/m2 for men) or left atrial volume index >34 ml/m2. ECG was performed in 983 patients and was considered abnormal in the presence of abnormal Q-waves; ST-T segment deviation or bundle branch block. We measured urine albumin (n=1,009) and proBNP/hs-TnI (n=933). The end-point of CV event was a composite of CV death and hospitalization with myocardial infarction/revascularization, stroke, peripheral artery disease or heart failure.

Results

The median follow-up was 4.7 years (interquartile range: 4.0 to 5.3) and 174 patients suffered an CVD event. All markers except hs-TnI were significantly (p<0.001) associated with the composite outcome: Abnormal echocardiogram: Hazard ratio (95% confidence interval): 2.39 (1.69–3.37); albuminuria 2.01 (1.47–2.76); abnormal ECG 2.35 (1.72–3.21); log2(proBNP) 1.60 (1.47–1.75) and hs-TnI 1.05 (0.92–1.19). The findings persisted after adjusting for clinical variables, but after adjusting for the other markers, only log2(proBNP) remained associated with the composite outcome (1.50 (0.20–1.73), p<0.001), figure. Measured by C-index model performance was highest with proBNP (0.70 (0.65–0.75)) and similar to clinical variables (0.71 (0.67–0.76)). Combining risk markers only resulted in very limited increase in C-index (echocardiogram, albuminuria, ECG and proBNP: 0.71 (0.66–0.76)).

Uni- and multivariables

Conclusions

This study identifies proBNP measurement in plasma over echocardiography, ECG and albuminuria for risk prediction in patients with type 2 diabetes. The diagnostic yield in considering more than one risk marker was limited in this population.